Voronoi
Business Services · South Korea · 51-200 Employees
View Company Info for Free
Overview
Headquarters
Songodogwahak-ro Yeonsu-gu it-Center Bld...Website
www.voronoi.ioRevenue
<$5 MillionIndustry
About Voronoi
Voronoi Org Chart
Is Voronoi your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Voronoi has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Voronoi recently announced quarterly report
Voronoi, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Voronoi
Click to see if Voronoi had a recent Job posting/layoffs
Product Launch: Get notified when Voronoi launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if Voronoi is spiking on competitors!
Funding: Get notified immidiatlly once Voronoi has new funding data
Recommended Actions
Find VP level buyers at Voronoi
Find more new buyers
Company Profile Activity
Activity Insights
Voronoi is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Voronoi is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Voronoi.
Voronoi Tech Stack
A closer look at the technologies used by Voronoi
Most Recent Scoops
Voronoi News & Media
Pyramid Biosciences Expands Precision Oncology Pipeline
WALTHAM, Mass., Nov. 16, 2021 /PRNewswire/ -- Pyramid Biosciences, Inc., a clinical-stage biotechnology company developing a portfolio of precision therapies targeting a wide range of diseases, today announced the global licensing of the novel monopolar spindle1 (MPS1) called VRN-08 and a...Brickell Biotech Acquires Exclusive Rights to Phase 1-Ready DYRK1A Inhibitor Program and Novel Platform Targeting Autoimmune and Inflammatory Diseases
Expect to initiate Phase 1 clinical study of lead DYRK1A inhibitor program, BBI-02, a potential first-in-class oral treatment for autoimmune and inflammatory diseases, in 2022
Top Business Services Companies
Top companies in Canada by revenue
Frequently Asked Questions Regarding Voronoi
VORONOI specializes in creating novel therapeutics with a focus on kinase inhibitors, utilizing their proprietary VORONOMICS platform to accelerate drug discovery. The company boasts a robust pipeline that leverages extensive experimental data to identify and optimize promising drug candidates. Their mission is to deliver targeted therapies that si... Read More